The two companies intend to develop jointly-branded clinical decision support software for faster accurate decision-making, allowing earlier diagnosis and individualized treatment.

The digital platform will use advanced analytics to provide workflow solutions and apps that support clinical decisions.

It will enable integration and analysis of in-vivo and in-vitro data, patient records, medical best practice, real time monitoring and the latest research outcomes.

Clinicians will get the comprehensive decision support to provide the correct treatment and quality of care for their patients.

Advanced analytics will be applied to in-vivo data from GE’s medical imaging and monitoring equipment with in-vitro data from biomarker, tissue pathology, genomics and sequencing portfolio of Roche.

GE Healthcare president & CEO Kieran Murphy said: “This is the first time that two major players in healthcare have combined advanced analytics with in-vivo and in-vitro diagnostics to this degree.

“We believe this alliance will help accelerate the delivery of data-driven precision health for customers, patients and the healthcare industry.”

Roche Diagnostics CEO Roland Diggelmann said the partnership will deliver new solutions and insights in clinical decision-making.

“Our goal is to support clinicians and other relevant stakeholders for the benefit of patients by providing the right decision support at the right time and through comprehensive digital offerings,” Diggelmann said.

GE Healthcare, which is the $18bn healthcare business of GE, harnesses data and analytics across hardware, software and biotech.

Roche creates innovative medicines and diagnostic tests that the company claims will help millions of patients globally.

Image: GE Healthcare has entered into a long-term partnership with Roche to jointly develop and co-market digital clinical decision support solutions. Photo: courtesy of General Electric.